Assembly of Celastrol to Zeolitic Imidazolate Framework-8 by Coordination as a Novel Drug Delivery Strategy for Cancer Therapy
Abstract
:1. Introduction
2. Results
2.1. Synthesis of Cel-ZIF-8 NPs
2.2. Characterization of Cel-ZIF-8 NPs
2.3. In Vitro Drug Release and Stability of Cel-ZIF-8 NPs
2.4. Cellular Uptake and Cytotoxicity Studies
2.5. In Vitro Apoptosis Assay of Cel-ZIF-8 NPs
3. Discussion
- (1)
- For micelles carriers [16], this nanomaterial is untargeted. Moreover, the loading capacity of Cel is ~5%, which is significantly lower than that reported in our work (~80%).
- (2)
- For MSN [15], the loading capacity of Cel is ~26%, which is also greatly lower than that of Cel-ZIF-8 (~80%). Additionally, the synthesis was conducted under a high temperature of 80 °C, while our Cel-ZIF-8 could swiftly assemble under room temperature.
- (3)
- For protein NPs [14], the loading capacity of Cel was not mentioned in the study. The synthesis steps of nanoparticles involved a longer time of ~3–4 days, and toxic organic solvents such as dichloromethane were utilized during the process. Nevertheless, our Cel-ZIF-8 was synthesized by the self-assembly of Cel, Zn2+, and 2-MIM via a simple one-pot method, which only involves about ~2 h. Additionally, the synthesis process was also environmentally friendly, for no toxic organic solvents were used in the synthesis.
- (4)
- For liposome carriers [13], this nanomaterial is untargeted, and the loading capacity of Cel was also unavailable. The synthesis involved an incubation time of 36 h, which is much longer than that of Cel-ZIF-8 (~2 h). In addition, toxic solvents such as chloroform were used during the synthesis, which is harmful to the environment.
- (1)
- Cel-ZIF-8 sharply improves the aqueous solubility of Cel by deprotonating its hydrogen atoms in hydroxyl and carboxyl, which vastly elevates the assembly efficacy from <1% to 80%.
- (2)
- Cel-ZIF-8 greatly elevates the bioavailability and cytotoxicity of Cel. In Section 2.4 and 2.5 (Figure 3 and Figure 4), the cellular uptake, cytotoxicity, and pro-apoptosis capabilities of Cel-ZIF-8 and Cel were comprehensively compared. Although the results were mostly similar, it should be noticed that the free Cel was actually dissolved in DMSO instead of an aqueous solution due to its low water solubility. In other words, the actual bioavailability of Cel is extremely low under physiological conditions. Therefore, it could be concluded that the Cel-ZIF-8 greatly improves the bioavailability of Cel.
- (3)
- Cel-ZIF-8 switches the bio-distribution of Cel from non-specific to pH-responsive targeted delivery, thus lowering the side effect of Cel. As depicted in Section 2.3, Cel-ZIF-8 maintains colloidal stability under physiological conditions (pH 7.4) while dissociating an acidic tumor microenvironment (pH 5.5). Additionally, it could be deduced from Figure 3a that RB molecules were loaded in Cel-ZIF-8, which enlightens us that another small and hydrophilic drug could also be loaded in Cel-ZIF-8 as a synergetic component of Cel.
4. Materials and Methods
4.1. Materials and Reagents
4.2. Synthesis of Cel-ZIF-8, Cel@ZIF-8, Cel/ZIF-8, and ZIF-8 Nanoparticles (NPs)
4.3. Determination of Cel Assembly Efficiency
4.4. Characterization of the ZIF-8 and Cel-ZIF-8 NPs
4.5. Cell Culture and Cytotoxicity Test
4.6. Cellular Uptake and Confocal Laser Scanning Microscopy (CLSM) Analysis
4.7. Detection of Apoptosis-Related Proteins by Western Blot
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Peng, S.Z.; Chen, X.H.; Chen, S.J.; Zhang, J.; Wang, C.Y.; Liu, W.R.; Zhang, D.; Su, Y.; Zhang, X.K. Phase separation of Nur77 mediates celastrol-induced mitophagy by promoting the liquidity of p62/SQSTM1 condensates. Nat. Commun. 2021, 12, 5989. [Google Scholar] [CrossRef] [PubMed]
- Duan, J.; Zhan, J.C.; Wang, G.Z.; Zhao, X.C.; Huang, W.D.; Zhou, G.B. The red wine component ellagic acid induces autophagy and exhibits anti-lung cancer activity in vitro and in vivo. J. Cell Mol. Med. 2019, 23, 143–154. [Google Scholar] [PubMed]
- Lin, F.Z.; Wang, S.C.; Hsi, Y.T.; Lo, Y.S.; Lin, C.C.; Chuang, Y.C.; Lin, S.H.; Hsieh, M.J.; Chen, M.K. Celastrol induces vincristine multidrug resistance oral cancer cell apoptosis by targeting JNK1/2 signaling pathway. Phytomedicine 2019, 54, 1–8. [Google Scholar] [CrossRef]
- Mi, C.; Shi, H.; Ma, J.; Han, L.Z.; Lee, J.J.; Jin, X. Celastrol induces the apoptosis of breast cancer cells and inhibits their invasion via downregulation of MMP-9. Oncol. Rep. 2014, 32, 2527–2532. [Google Scholar] [CrossRef] [PubMed]
- Yang, P.; Dong, F.; Zhou, Q. Triptonide acts as a novel potent anti-lymphoma agent with low toxicity mainly through inhibition of proto-oncogene Lyn transcription and suppression of Lyn signal pathway. Toxicol. Lett. 2017, 278, 9–17. [Google Scholar] [CrossRef] [PubMed]
- Chan, S.F.; Chen, Y.Y.; Lin, J.J.; Liao, C.L.; Ko, Y.C.; Tang, N.Y.; Kuo, C.L.; Liu, K.C.; Chung, J.G. Triptolide induced cell death through apoptosis and autophagy in murine leukemia WEHI-3 cells in vitro and promoting immune responses in WEHI-3 generated leukemia mice in vivo. Environ. Toxicol. 2017, 32, 550–568. [Google Scholar] [CrossRef]
- Shanmugam, M.K.; Ahn, K.S.; Lee, J.H.; Kannaiyan, R.; Mustafa, N.; Manu, K.A.; Siveen, K.S.; Sethi, G.; Chng, W.J.; Kumar, A.P. Celastrol Attenuates the Invasion and Migration and Augments the Anticancer Effects of Bortezomib in a Xenograft Mouse Model. of Multiple Myeloma. Front. Pharmacol. 2018, 9, 365. [Google Scholar] [CrossRef]
- Bai, X.; Fu, R.J.; Zhang, S.; Yue, S.J.; Chen, Y.Y.; Xu, D.Q.; Tang, Y.P. Potential medicinal value of celastrol and its synthesized analogues for central nervous system diseases. Biomed. Pharmacother. 2021, 139, 111551. [Google Scholar] [CrossRef]
- Wu, J.; Ding, M.; Mao, N.; Wu, Y.; Wang, C.; Yuan, J.; Miao, X.; Li, J.; Shi, Z. Celastrol inhibits chondrosarcoma proliferation, migration and invasion through suppression CIP2A/c-MYC signaling pathway. J. Pharmacol. Sci. 2017, 134, 22–28. [Google Scholar] [CrossRef]
- Li, X.; Wang, H.; Ding, J.; Nie, S.; Wang, L.; Zhang, L.; Ren, S. Celastrol strongly inhibits proliferation, migration and cancer stem cell properties through suppression of Pin1 in ovarian cancer cells. Eur. J. Pharmacol. 2019, 842, 146–156. [Google Scholar] [CrossRef]
- Zhang, J.; Wang, R.; Cheng, L.; Xu, H. Celastrol inhibit the proliferation, invasion and migration of human cervical HeLa cancer cells through down-regulation of MMP-2 and MMP-9. J. Cell Mol. Med. 2021, 25, 5335–5338. [Google Scholar] [CrossRef] [PubMed]
- Dai, C.H.; Zhu, L.R.; Wang, Y.; Tang, X.P.; Du, Y.J.; Chen, Y.C.; Li, J. Celastrol acts synergistically with afatinib to suppress non-small cell lung cancer cell proliferation by inducing paraptosis. J. Cell Physiol. 2021, 236, 4538–4554. [Google Scholar] [CrossRef] [PubMed]
- Chen, X.; Hu, X.; Hu, J.; Qiu, Z.; Yuan, M.; Zheng, G. Celastrol-Loaded Galactosylated Liposomes Effectively Inhibit AKT/c-Met-Triggered Rapid Hepatocarcinogenesis in Mice. Mol. Pharm. 2020, 17, 738–747. [Google Scholar] [CrossRef] [PubMed]
- Guo, L.; Luo, S.; Du, Z.; Zhou, M.; Li, P.; Fu, Y.; Sun, X.; Huang, Y.; Zhang, Z. Targeted delivery of celastrol to mesangial cells is effective against mesangioproliferative glomerulonephritis. Nat. Commun. 2017, 8, 878. [Google Scholar] [CrossRef]
- Choi, J.Y.; Gupta, B.; Ramasamy, T.; Jeong, J.H.; Jin, S.G.; Choi, H.G.; Yong, C.S.; Kim, J.O. PEGylated polyaminoacid-capped mesoporous silica nanoparticles for mitochondria-targeted delivery of celastrol in solid tumors. Colloids Surf. B Biointerfaces 2018, 165, 56–66. [Google Scholar] [CrossRef] [PubMed]
- Peng, X.; Liang, Y.; Li, J.; Lin, L.; Wang, J.; Yin, Y.; Liao, H.; Li, L. Preventive effects of “ovalbumin-conjugated celastrol-loaded nanomicelles” in a mouse model of ovalbumin-induced allergic airway inflammation. Eur. J. Pharm. Sci. 2020, 143, 105172. [Google Scholar] [CrossRef] [PubMed]
- Ge, P.; Niu, B.; Wu, Y.; Xu, W.; Li, M.; Sun, H.; Zhou, H.; Zhang, X.; Xie, J. Enhanced cancer therapy of celastrol in vitro and in vivo by smart dendrimers delivery with specificity and biosafety. Chem. Eng. J. 2020, 383, 123228. [Google Scholar] [CrossRef]
- Chen, X.; Tong, R.; Shi, Z.; Yang, B.; Liu, H.; Ding, S.; Wang, X.; Lei, Q.; Wu, J.; Fang, W. MOF Nanoparticles with Encapsulated Autophagy Inhibitor in Controlled Drug Delivery System for Antitumor. ACS Appl. Mater. Interfaces 2018, 10, 2328–2337. [Google Scholar] [CrossRef]
- Son, Y.-R.; Ryu, S.G.; Kim, H.S. Rapid adsorption and removal of sulfur mustard with zeolitic imidazolate frameworks ZIF-8 and ZIF-67. Microporous Mesoporous Mater. 2020, 293, 109819. [Google Scholar] [CrossRef]
- Tan, G.; Zhong, Y.; Yang, L.; Jiang, Y.; Liu, J.; Ren, F. A multifunctional MOF-based nanohybrid as injectable implant platform for drug synergistic oral cancer therapy. Chem. Eng. J. 2020, 390, 124446. [Google Scholar] [CrossRef]
- Shen, X.; Yie, K.H.R.; Wu, X.; Zhou, Z.; Sun, A.; Al-bishari, A.M.; Fang, K.; Al-Baadani, M.A.; Deng, Z.; Ma, P.; et al. Improvement of aqueous stability and anti-osteoporosis properties of Zn-MOF coatings on titanium implants by hydrophobic raloxifene. Chem. Eng. J. 2022, 430, 133094. [Google Scholar] [CrossRef]
- Ahmed, M.K.; Moydeenb, A.M.; Ismailc, A.M.; El-Naggard, M.E.; Menazeace, A.A.; El-Newehy, M.H. Wound dressing properties of functionalized environmentally biopolymer loaded with selenium nanoparticles. J. Mol. Struct. 2021, 1225, 129138. [Google Scholar] [CrossRef]
- Lawson, H.D.; Walton, S.P.; Chan, C. Metal—Organic Frameworks for Drug Delivery: A Design Perspective. ACS Appl. Mater. Interfaces 2021, 13, 7004–7020. [Google Scholar] [CrossRef] [PubMed]
- Cheng, X.; Zhu, Z.; Liu, Y.; Xue, Y.; Gao, X.; Wang, J.; Pei, X.; Wan, Q. Zeolitic Imidazolate Framework-8 Encapsulating Risedronate Synergistically Enhances Osteogenic and Antiresorptive Properties for Bone Regeneration. ACS Biomater. Sci. Eng. 2020, 6, 2186–2197. [Google Scholar] [CrossRef]
- Wang, Z.; Tang, X.; Wang, X.; Yang, D.; Yang, C.; Lou, Y.; Chen, J.; He, N. Near-infrared light-induced dissociation of zeolitic imidazole framework-8 (ZIF-8) with encapsulated CuS nanoparticles and their application as a therapeutic nanoplatform. Chem. Commun. 2016, 52, 12210–12213. [Google Scholar] [CrossRef] [PubMed]
- Xiong, M.; Zhang, M.; Liu, Q.; Yang, C.; Xie, Q.; Ke, G.; Meng, H.M.; Zhang, X.B.; Tan, W. Biomineralized nanoparticles enable an enzyme-assisted DNA signal amplification in living cells. Chem. Commun. 2020, 56, 2901–2904. [Google Scholar] [CrossRef]
- Zhang, K.; Le, X.; Yu, Q.; Zhang, J.; Wang, D.; Chen, T.; Chu, X. Biomineralized zeolitic imidazolate framework-8 nanoparticles enable polymerase/endonuclease synergetic amplification reaction in living cells for sensitive microRNA imaging. Chem. Commun. 2021, 57, 8472–8475. [Google Scholar] [CrossRef]
- Feng, S.; Zhang, X.; Shi, D.; Wang, Z. Zeolitic imidazolate framework-8 (ZIF-8) for drug delivery: A critical review. Front. Chem. Sci. Eng. 2020, 15, 221–237. [Google Scholar] [CrossRef]
- Zheng, H.; Zhang, Y.; Liu, L.; Wan, W.; Guo, P.; Nyström, A.M.; Zou, X. One-pot Synthesis of Metal-Organic Frameworks with Encapsulated Target Molecules and Their Applications for Controlled Drug Delivery. J. Am. Chem. Soc. 2016, 138, 962–968. [Google Scholar] [CrossRef]
- Zhang, X.; Wang, J.; Wu, J.; Jiang, X.; Pei, X.; Chen, J.; Wan, Q.; Huang, C. Dimethyloxalylglycine improves angiogenesis of ZIF-8-coated implant. J. Biomater. Appl. 2019, 34, 396–407. [Google Scholar] [CrossRef]
- Sun, C.Y.; Qin, C.; Wang, X.L.; Yang, G.S.; Shao, K.Z.; Lan, Y.Q.; Su, Z.M.; Huang, P.; Wang, C.G.; Wang, E.B. Zeolitic Imidazolate framework-8 as efficient pH-sensitive drug delivery vehicle. Dalton. Trans. 2012, 41, 6906–6909. [Google Scholar] [CrossRef] [PubMed]
- Palao-Suay, R.; Aguilar, M.R.; Parra-Ruiz, F.J.; Fernández-Gutiérrez, M.; Parra, J.; Sánchez-Rodríguez, C.; Sanz-Fernández, R.; Rodrigáñez, L.; Román, J.S. Anticancer and antiangiogenic activity of surfactant-free nanoparticles based on self-assembled polymeric derivatives of vitamin E: Structure-activity relationshi. Biomacromolecules 2015, 16, 1566–1581. [Google Scholar] [CrossRef] [PubMed]
- Kozlovskaya, V.; Liu, F.; Xue, B.; Ahmad, F.; Alford, A.; Saeed, M.; Kharlampieva, E. Polyphenolic Polymersomes of Temperature-Sensitive Poly(N-vinylcaprolactam)-block-Poly(N-vinylpyrrolidone) for Anticancer Therapy. Biomacromolecules 2017, 18, 2552–2563. [Google Scholar] [CrossRef]
- Zhang, H.; Jiang, W.; Liu, R.; Zhang, J.; Zhang, D.; Li, Z.; Luan, Y. Rational Design of Metal. Organic Framework Nanocarrier-Based Codelivery System of Doxorubicin Hydrochloride/Verapamil Hydrochloride for Overcoming Multidrug Resistance with Efficient Targeted Cancer Therapy. ACS Appl. Mater. Interfaces 2017, 9, 19687–19697. [Google Scholar] [CrossRef]
- Han, Y.; Li, M.; Lai, J.; Li, W.; Liu, Y.; Yin, L.; Yang, L.; Xue, X.; Vajtai, R.; Ajayan, P.M.; et al. Rational Design of Oxygen-Enriched Carbon Dots with Efficient Room-Temperature Phosphorescent Properties and High-Tech Security Protection Application. ACS Sustain. Chem. Eng. 2019, 7, 19918–19924. [Google Scholar] [CrossRef]
- Li, P.; Zhou, X.Y.; Qu, D.; Guo, M.; Fan, C.; Zhou, T.; Ling, Y. Preliminary study on fabrication, characterization and synergistic anti-lung cancer effects of self-assembled micelles of covalently conjugated celastrol-polyethylene glycol-ginsenoside Rh2. Drug Deliv. 2017, 24, 834–845. [Google Scholar] [CrossRef] [PubMed]
- Law, S.; Leung, A.W.; Xu, C. Folic acid-modified celastrol nanoparticles: Synthesis, characterization, anticancer activity in 2D and 3D breast cancer models. Artif. Cells Nanomed. Biotechnol. 2020, 48, 542–559. [Google Scholar] [CrossRef]
- Deng, J.; Wang, K.; Wang, M.; Yu, P.; Mao, L. Mitochondria Targeted Nanoscale Zeolitic Imidazole Framework-90 for ATP Imaging in Live Cells. J. Am. Chem. Soc. 2017, 139, 5877–5882. [Google Scholar] [CrossRef]
- Zhuang, J.; Gong, H.; Zhou, J.; Zhang, Q.; Gao, W.; Fang, R.H.; Zhang, L. Targeted gene silencing in vivo by platelet membrane–coated metal-organic framework nanoparticles. Sci. Adv. 2020, 6, eaaz6108. [Google Scholar] [CrossRef] [Green Version]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Wang, N.; Li, Y.; He, F.; Liu, S.; Liu, Y.; Peng, J.; Liu, J.; Yu, C.; Wang, S. Assembly of Celastrol to Zeolitic Imidazolate Framework-8 by Coordination as a Novel Drug Delivery Strategy for Cancer Therapy. Pharmaceuticals 2022, 15, 1076. https://doi.org/10.3390/ph15091076
Wang N, Li Y, He F, Liu S, Liu Y, Peng J, Liu J, Yu C, Wang S. Assembly of Celastrol to Zeolitic Imidazolate Framework-8 by Coordination as a Novel Drug Delivery Strategy for Cancer Therapy. Pharmaceuticals. 2022; 15(9):1076. https://doi.org/10.3390/ph15091076
Chicago/Turabian StyleWang, Na, Yifan Li, Fei He, Susu Liu, Yuan Liu, Jinting Peng, Jiahui Liu, Changyuan Yu, and Shihui Wang. 2022. "Assembly of Celastrol to Zeolitic Imidazolate Framework-8 by Coordination as a Novel Drug Delivery Strategy for Cancer Therapy" Pharmaceuticals 15, no. 9: 1076. https://doi.org/10.3390/ph15091076
APA StyleWang, N., Li, Y., He, F., Liu, S., Liu, Y., Peng, J., Liu, J., Yu, C., & Wang, S. (2022). Assembly of Celastrol to Zeolitic Imidazolate Framework-8 by Coordination as a Novel Drug Delivery Strategy for Cancer Therapy. Pharmaceuticals, 15(9), 1076. https://doi.org/10.3390/ph15091076